{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T02:28:14Z","timestamp":1793327294756,"version":"4.5.0"},"reference-count":159,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1097\/tp.0000000000000869","type":"journal-article","created":{"date-parts":[[2015,8,26]],"date-time":"2015-08-26T20:11:07Z","timestamp":1440619867000},"page":"39-53","source":"Crossref","is-referenced-by-count":111,"title":["The Influence of Immunosuppressive Agents on the Risk of De Novo Donor-Specific HLA Antibody Production in Solid Organ Transplant Recipients"],"prefix":"10.1097","volume":"100","author":[{"given":"Jacqueline G.","family":"O'Leary","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Millie","family":"Samaniego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Crespo Barrio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciano","family":"Potena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Zeevi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arjang","family":"Djamali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Cozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-12-20210129","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1056\/NEJMoa1302506","article-title":"Complement-binding anti-HLA antibodies and kidney-allograft survival.","volume":"369","author":"Loupy","year":"2013","journal-title":"N Engl J Med"},{"key":"R2-12-20210129","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1111\/j.1600-6143.2006.01711.x","article-title":"Extremely high association between appearance of HLA antibodies and failure of kidney grafts in a five-year longitudinal study.","volume":"7","author":"Mao","year":"2007","journal-title":"Am J Transplant"},{"key":"R3-12-20210129","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1097\/TP.0b013e3181b11b72","article-title":"HLA-specific antibodies developed in the first year posttransplant are predictive of chronic rejection and renal graft loss.","volume":"88","author":"Lee","year":"2009","journal-title":"Transplantation"},{"key":"R4-12-20210129","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1681\/ASN.2004121130","article-title":"Frequency and clinical implications of development of donor-specific and non-donor- specific HLA antibodies after kidney transplantation.","volume":"16","author":"Hourmant","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"R5-12-20210129","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1681\/ASN.2007070736","article-title":"Antibody-mediated rejection of the kidney after simultaneous pancreas-kidney transplantation.","volume":"19","author":"Pascual","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"R6-12-20210129","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1111\/ajt.12212","article-title":"De novo donor-specific HLA antibodies decrease patient and graft survival in liver transplant recipients.","volume":"13","author":"Kaneku","year":"2013","journal-title":"Am J Transplant"},{"key":"R7-12-20210129","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1111\/ajt.12147","article-title":"Class II alloantibody and mortality in simultaneous liver-kidney transplantation.","volume":"13","author":"OLeary","year":"2013","journal-title":"Am J Transplant"},{"key":"R8-12-20210129","doi-asserted-by":"crossref","first-page":"3047","DOI":"10.1111\/j.1600-6143.2012.04237.x","article-title":"Preformed and de novo donor specific antibodies in visceral transplantation:long-term outcome with special reference to the liver.","volume":"12","author":"Abu-Elmagd","year":"2012","journal-title":"Am J Transplant"},{"key":"R9-12-20210129","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/j.1600-6143.2010.03383.x","article-title":"De novo donor HLA-specific antibodies after heart transplantation are an independent predictor of poor patient survival.","volume":"11","author":"Smith","year":"2011","journal-title":"Am J Transplant"},{"key":"R10-12-20210129","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.humimm.2010.10.013","article-title":"Pre- and posttransplantation allosensitization in heart allograft recipients: major impact of de novo alloantibody production on allograft survival.","volume":"72","author":"Ho","year":"2011","journal-title":"Hum Immunol"},{"key":"R11-12-20210129","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1378\/chest.12-0587","article-title":"Implications for human leukocyte antigen antibodies after lung transplantation: a 10-year experience in 441 patients.","volume":"144","author":"Snyder","year":"2013","journal-title":"Chest"},{"key":"R12-12-20210129","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.humimm.2010.02.021","article-title":"Development of antibodies to human leukocyte antigen precedes development of antibodies to major histocompatibility class I-related chain A and are significantly associated with development of chronic rejection after human lung transplantation.","volume":"71","author":"Angaswamy","year":"2010","journal-title":"Hum Immunol"},{"key":"R13-12-20210129","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.2337\/db12-1258","article-title":"Alloantibody and autoantibody monitoring predicts islet transplantation outcome in human type 1 diabetes.","volume":"62","author":"Piemonti","year":"2013","journal-title":"Diabetes"},{"key":"R14-12-20210129","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/j.healun.2014.07.012","article-title":"De novo donor HLA-specific antibodies predict development of bronchiolitis obliterans syndrome after lung transplantation.","volume":"33","author":"Safavi","year":"2014","journal-title":"J Heart Lung Transplant"},{"key":"R15-12-20210129","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1097\/TP.0b013e318273878c","article-title":"Donor-specific antibodies to class II antigens are associated with accelerated cardiac allograft vasculopathy: a three-dimensional volumetric intravascular ultrasound study.","volume":"95","author":"Topilsky","year":"2013","journal-title":"Transplantation"},{"key":"R16-12-20210129","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.trim.2013.05.001","article-title":"Pre-transplant donor specific anti-HLA antibody is associated with antibody-mediated rejection, progressive graft dysfunction and patient death.","volume":"28","author":"Fidler","year":"2013","journal-title":"Transpl Immunol"},{"key":"R17-12-20210129","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1097\/TP.0b013e3182543950","article-title":"De novo DQ donor-specific antibodies are associated with a significant risk of antibody-medicate rejection and transplant glomerulopathy.","volume":"94","author":"Willicombe","year":"2012","journal-title":"Transplantation"},{"key":"R18-12-20210129","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1111\/tri.12330","article-title":"Conversion to mammalian target of rapamycin inhibitors increases risk of de novo donor-specific antibodies.","volume":"27","author":"Croze","year":"2014","journal-title":"Transpl Int"},{"key":"R19-12-20210129","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1111\/tri.12316","article-title":"DQ molecules are the principal stimulators of de novo donor specific antibodies in non sensitized pediatric recipients receiving a first kidney transplant.","volume":"27","author":"Tagliamacco","year":"2014","journal-title":"Transpl Int"},{"key":"R20-12-20210129","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1097\/01.TP.0000436927.08026.a8","article-title":"Increased negative impact of donor HLA-specific together with non-HLA-specific antibodies on graft outcome.","volume":"97","author":"Reinsmoen","year":"2014","journal-title":"Transplantation"},{"key":"R21-12-20210129","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1097\/PAS.0b013e31825197ae","article-title":"The histopathology of lung allograft dysfunction associated with the development of donor-specific HLA alloantibodies.","volume":"36","author":"Yousem","year":"2012","journal-title":"Am J Surg Pathol"},{"key":"R22-12-20210129","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1097\/TP.0b013e31829434d4","article-title":"Early versus late acute antibody-mediated rejection in renal transplant recipients.","volume":"96","author":"Dorje","year":"2013","journal-title":"Transplantation"},{"key":"R23-12-20210129","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/j.1600-6143.2011.03840.x","article-title":"Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence.","volume":"12","author":"Sellares","year":"2012","journal-title":"Am J Transplant"},{"key":"R24-12-20210129","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1097\/TP.0b013e3182126ed0","article-title":"Natural history of proteinuria in renal transplant recipients developing de novo human leukocyte antigen antibodies.","volume":"91","author":"Fotheringham","year":"2011","journal-title":"Transplantation"},{"key":"R25-12-20210129","doi-asserted-by":"crossref","first-page":"2874","DOI":"10.1016\/j.transproceed.2010.07.079","article-title":"De novo anti-HLA antibodies in renal allograft recipients: a cross-section study.","volume":"42","author":"Sanchez-Fructuoso","year":"2010","journal-title":"Transplant Proc"},{"key":"R26-12-20210129","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1111\/j.1600-6143.2006.01688.x","article-title":"Banff 05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy (CAN).","volume":"7","author":"Solez","year":"2007","journal-title":"Am J Transplant"},{"key":"R27-12-20210129","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/j.suc.2013.08.002","article-title":"Management of antibody-mediated rejection in transplantation.","volume":"93","author":"Sadaka","year":"2013","journal-title":"Surg Clin North Am"},{"key":"R28-12-20210129","first-page":"414","article-title":"Antibody-mediated rejection in heart transplant patients: long-term follow up of patients with high levels of donor-directed anti-DQ antibodies.","volume":"409-","author":"Ticehurst","year":"2011","journal-title":"Clin Transpl"},{"key":"R29-12-20210129","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1111\/ajt.12667","article-title":"The role of donor-specific HLA alloantibodies in liver transplantation.","volume":"14","author":"OLeary","year":"2014","journal-title":"Am J Transplant"},{"key":"R30-12-20210129","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1002\/lt.23854","article-title":"Donor-specific alloantibodies are associated with fibrosis progression after liver-transplantation in HCV-infected patients.","volume":"20","author":"OLeary","year":"2014","journal-title":"Liver Transpl"},{"key":"R31-12-20210129","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/j.healun.2014.07.018","article-title":"De novo donor-specific HLA antibodies are associated with early and high-grade bronchiolitis syndrome and death after lung transplantation.","volume":"33","author":"Morrell","year":"2014","journal-title":"J Heart Lung Transplant"},{"key":"R32-12-20210129","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.healun.2012.10.007","article-title":"Donor-specific antibodies are associated with antibody-mediated rejection, acute cellular rejection, bronchiolitis obliterans syndrome, and cystic fibrosis after lung transplantation.","volume":"32","author":"Lobo","year":"2013","journal-title":"J Heart Lung Transplant"},{"key":"R33-12-20210129","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/TP.0b013e31827a19cc","article-title":"Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation.","volume":"95","author":"Tait","year":"2013","journal-title":"Transplantation"},{"key":"R34-12-20210129","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1111\/ajt.12462","article-title":"Comprehensive assessment and standardization of solid phase multiplex-bead arrays for the detection of antibodies to HLA-drilling down on key sources of variation.","volume":"13","author":"Reed","year":"2013","journal-title":"Am J Transplant"},{"key":"R35-12-20210129","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1097\/TP.0b013e3182888db6","article-title":"The role of immunoglobulin-G subclasses and C1q in de novo HLA-DQ donor-specific antibody kidney transplantation outcomes.","volume":"95","author":"Freitas","year":"2013","journal-title":"Transplantation"},{"key":"R36-12-20210129","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1097\/TP.0b013e318203fd26","article-title":"C1q-fixing human leukocyte antigen antibodies are specific for predicting transplant glomerulopathy and late graft failure after kidney transplantation.","volume":"91","author":"Yabu","year":"2011","journal-title":"Transplantation"},{"key":"R37-12-20210129","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1097\/TP.0b013e31829c2481","article-title":"On the detection of anti-HLA antibodies using single antigen bead Luminex assay: lot-to-lot variations in MFI.","volume":"96","author":"Friedlander","year":"2013","journal-title":"Transplantation"},{"key":"R38-12-20210129","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.transproceed.2004.12.066","article-title":"New crossmatch technique eliminates interference by humanized and chimeric monoclonal antibodies.","volume":"37","author":"Book","year":"2005","journal-title":"Transplant Proc"},{"key":"R39-12-20210129","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1016\/j.humimm.2013.08.278","article-title":"Very low residual concentrations of rituximab long after infusion still induce positive B-cell complement-dependent cytotoxicity-crossmatch.","volume":"74","author":"Gatault","year":"2013","journal-title":"Hum Immunol"},{"key":"R40-12-20210129","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1097\/01.tp.0000269615.91036.52","article-title":"The effect of antithymocyte globulin on anti-human leukocyte antigen antibody detection assays.","volume":"84","author":"Gloor","year":"2007","journal-title":"Transplantation"},{"key":"R41-12-20210129","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1111\/j.1600-6143.2012.04013.x","article-title":"Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant.","volume":"12","author":"Wiebe","year":"2012","journal-title":"Am J Transplant"},{"key":"R42-12-20210129","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1097\/TP.0b013e3182139da1","article-title":"Inferior kidney allograft outcomes in patients with de novo donor-specific antibodies are due to acute rejection episodes.","volume":"91","author":"Cooper","year":"2011","journal-title":"Transplantation"},{"key":"R43-12-20210129","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1038\/ki.2012.190","article-title":"Donor-specific HLA-DQ antibodies may contribute to poor graft outcome after renal transplantation.","volume":"82","author":"DeVos","year":"2012","journal-title":"Kidney Int"},{"key":"R44-12-20210129","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.trim.2010.12.003","article-title":"Detection of antibodies against HLA-C epitopes in patients with rejected kidney transplants.","volume":"24","author":"Duquesnoy","year":"2011","journal-title":"Transpl Immunol"},{"key":"R45-12-20210129","doi-asserted-by":"crossref","first-page":"3114","DOI":"10.1111\/ajt.12478","article-title":"Class II HLA epitope matchinga strategy to minimize de novo donor-specific antibody development and improve outcomes.","volume":"13","author":"Wiebe","year":"2013","journal-title":"Am J Transplant"},{"key":"R46-12-20210129","first-page":"157","article-title":"Epitope analysis of HLA-DQ antigens: what does the antibody see Transplantation.","volume":"98","author":"Tambur","year":"2014","journal-title":""},{"key":"R47-12-20210129","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1111\/ajt.12651","article-title":"Prevalence, incidence and risk factors for donor-specific anti-HLA antibodies in maintenance liver transplant patients.","volume":"14","author":"Del Bello","year":"2014","journal-title":"Am J Transplant"},{"key":"R48-12-20210129","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1016\/j.transproceed.2011.06.053","article-title":"Donor-specific HLA antibodies: risk factors and outcomes after kidney transplantation.","volume":"43","author":"Kanter Berga","year":"2011","journal-title":"Transplant Proc"},{"key":"R49-12-20210129","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/ctr.12127","article-title":"Incidence of donor-specific antibodies in kidney transplant patients following conversion to an everolimus-based calcineurin inhibitor-free regimen.","volume":"27","author":"Kamar","year":"2013","journal-title":"Clin Transplant"},{"key":"R50-12-20210129","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1681\/ASN.2014010119","article-title":"Persistent BK viremia does not increase intermediate-term graft loss but is associated with de novo donor-specific antibodies.","volume":"26","author":"Sawinski","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"R51-12-20210129","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1111\/j.1600-6143.2012.03995.x","article-title":"Prevalence, course and impact of HLA donor-specific antibodies in liver transplantation in the first year.","volume":"12","author":"Taner","year":"2012","journal-title":"Am J Transplant"},{"key":"R52-12-20210129","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1016\/S0198-8859(99)00104-4","article-title":"Shared cadaver donor-husband HLA class I mismatches as a risk factor for renal graft rejection in previously pregnant women.","volume":"60","author":"Pollack","year":"1999","journal-title":"Hum Immunol"},{"key":"R53-12-20210129","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.humimm.2003.12.007","article-title":"Unappreciated risk factors for transplant patients: HLA antibodies in blood components.","volume":"65","author":"Bray","year":"2004","journal-title":"Hum Immunol"},{"key":"R54-12-20210129","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1111\/j.1600-6143.2011.03961.x","article-title":"Donor-specific HLA antibodies in a cohort comparing everolimus with cyclosporine after kidney transplantation.","volume":"12","author":"Liefeldt","year":"2012","journal-title":"Am J Transplant"},{"key":"R55-12-20210129","first-page":"256","article-title":"Incidences of preformed and de novo donor-specific HLA antibodies and their clinicohistological correlates in the early course of kidney transplantation.","volume":"247-","author":"Huang","year":"2012","journal-title":"Clin Transpl"},{"key":"R56-12-20210129","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1097\/TP.0b013e31817fdddb","article-title":"Effect on kidney graft survival of reducing or discontinuing maintenance immunosuppression after the first year posttransplant.","volume":"86","author":"Opelz","year":"2008","journal-title":"Transplantation"},{"key":"R57-12-20210129","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/j.1399-0012.2009.01056.x","article-title":"Non-adherence to immunosuppressive medication in renal transplant recipients within the scope of the Integrative Model of Behavioral Prediction: a cross-sectional study.","volume":"24","author":"Schmid-Mohler","year":"2010","journal-title":"Clin Transplant"},{"key":"R58-12-20210129","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/tri.12312","article-title":"Psychosocial Interest Group; Swiss Transplant Cohort Study. Describing the evolution of medication nonadherence from pretransplant until 3 years post-transplant and determining pretransplant medication nonadherence as risk factor for post-transplant nonadherence to immunosuppressives: the Swiss Transplant Cohort Study.","volume":"27","author":"De Geest","year":"2014","journal-title":"Transpl Int"},{"key":"R59-12-20210129","first-page":"400","article-title":"Targeted monitoring of donor-specific HLA antibodies following renal transplantation.","volume":"395-","author":"Almeshari","year":"2011","journal-title":"Clin Transpl"},{"key":"R60-12-20210129","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1097\/01.TP.0000442503.85766.91","article-title":"Late antibody-mediated rejection in renal allografts: outcome after conventional and novel therapies.","volume":"97","author":"Gupta","year":"2014","journal-title":"Transplantation"},{"key":"R61-12-20210129","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/petr.12247","article-title":"Pediatric kidney recipients may benefit from monitoring for donor-specific antibodies.","volume":"18","author":"Athavale","year":"2014","journal-title":"Pediatr Transplant"},{"key":"R62-12-20210129","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1034\/j.1600-6143.2003.30113.x","article-title":"Acute humoral rejection in hepatitis C-infected renal transplant recipients receiving antiviral therapy.","volume":"3","author":"Baid","year":"2003","journal-title":"Am J Transplant"},{"key":"R63-12-20210129","doi-asserted-by":"crossref","first-page":"2966","DOI":"10.1111\/ajt.12413","article-title":"Plasma cell hepatitis in liver allografts: identification and characterization of an IgG4-rich cohort.","volume":"13","author":"Castillo-Rama","year":"2013","journal-title":"Am J Transplant"},{"key":"R64-12-20210129","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1097\/01.TP.0000438636.52085.50","article-title":"Regulation of anti-HLA antibody-dependent natural killer cell activation by immunosuppressive agents.","volume":"97","author":"Shin","year":"2014","journal-title":"Transplantation"},{"key":"R65-12-20210129","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1097\/TP.0b013e3181949d2e","article-title":"No occurrence of de novo HLA antibodies in patients with early corticosteroid withdrawal in a 5-year prospective randomized study.","volume":"87","author":"Delgado","year":"2009","journal-title":"Transplantation"},{"key":"R66-12-20210129","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1097\/TP.0b013e3181fc8937","article-title":"Efficacy and safety of thymoglobulin induction as an alternative approach for steroid-free maintenance immunosuppression in pediatric renal transplantation.","volume":"90","author":"Li","year":"2010","journal-title":"Transplantation"},{"key":"R67-12-20210129","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1592\/phco.26.12.1771","article-title":"Rabbit antithymocyte globulin induction therapy in adult renal transplantation.","volume":"26","author":"Hardinger","year":"2006","journal-title":"Pharmacotherapy"},{"key":"R68-12-20210129","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.trim.2012.02.003","article-title":"The effect of low and ultra-low dosages thymoglobulin on peripheral T, B and NK cells in kidney transplant recipients.","volume":"26","author":"Kho","year":"2012","journal-title":"Transpl Immunol"},{"key":"R69-12-20210129","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1034\/j.1600-6143.2003.00120.x","article-title":"Campath-1H induction plus rapamycin monotherapy for renal transplantation: results of a pilot study.","volume":"3","author":"Knechtle","year":"2003","journal-title":"Am J Transplant"},{"key":"R70-12-20210129","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/01.tp.0000191940.13473.59","article-title":"T-lymphocyte alloresponses of Campath-1H-treated kidney transplant patients.","volume":"81","author":"Bloom","year":"2006","journal-title":"Transplantation"},{"key":"R71-12-20210129","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1111\/j.1600-6143.2010.03050.x","article-title":"Investigation of lymphocyte depletion and repopulation using alemtuzumab (Campath-1H) in cynomolgus monkeys.","volume":"10","author":"van der Windt","year":"2010","journal-title":"Am J Transplant"},{"key":"R72-12-20210129","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1111\/tri.12072","article-title":"Rituximab in renal transplantation.","volume":"26","author":"Barnett","year":"2013","journal-title":"Transpl Int"},{"key":"R73-12-20210129","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/ki.2014.261","article-title":"A closer look at rituximab induction on HLA antibody rebound following HLA-incompatible kidney transplantation.","volume":"87","author":"Jackson","year":"2015","journal-title":"Kidney Int"},{"key":"R74-12-20210129","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/ajt.13052","article-title":"Rituximab as induction therapy after renal transplantation: a randomized, double-blind, placebo-controlled study of efficacy and safety.","volume":"15","author":"van den Hoogen","year":"2015","journal-title":"Am J Transplant"},{"key":"R75-12-20210129","first-page":"392","article-title":"Bortezomib affects the function of human B cells: possible implications for desensitization protocols.","volume":"387-","author":"Heidt","year":"2009","journal-title":"Clin Transpl"},{"key":"R76-12-20210129","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1056\/NEJMoa0707894","article-title":"Rituximab and intravenous immune globulin for desensitization during renal transplantation.","volume":"359","author":"Vo","year":"2008","journal-title":"N Engl J Med"},{"key":"R77-12-20210129","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1097\/TP.0000000000000064","article-title":"Benefits of rituximab combined with intravenous immunoglobulin for desensitization in kidney transplant recipients.","volume":"98","author":"Vo","year":"2014","journal-title":"Transplantation"},{"key":"R78-12-20210129","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/j.1365-2249.2009.04051.x","article-title":"Calcineurin inhibitors affect B cell antibody responses indirectly by interfering with T cell help.","volume":"159","author":"Heidt","year":"2010","journal-title":"Clin Exp Immunol"},{"key":"R79-12-20210129","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0162-3109(00)00190-9","article-title":"The use of mycophenolate mofetil in transplant recipients.","volume":"47","author":"Mele","year":"2000","journal-title":"Immunopharmacology"},{"key":"R80-12-20210129","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.trim.2010.12.002","article-title":"Mesenchymal stem cells together with mycophenolate mofetil inhibit antigen presenting cell and T cell infiltration into allogeneic heart grafts.","volume":"24","author":"Eggenhofer","year":"2011","journal-title":"Transpl Immunol"},{"key":"R81-12-20210129","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1097\/MOT.0b013e32835a4be2","article-title":"Mechanistic target of rapamycin inhibitors in solid organ transplantation: from benchside to clinical use.","volume":"17","author":"Touzot","year":"2012","journal-title":"Curr Opin Organ Transplant"},{"key":"R82-12-20210129","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S0009-9120(98)00045-9","article-title":"Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression.","volume":"31","author":"Sehgal","year":"1998","journal-title":"Clin Biochem"},{"key":"R83-12-20210129","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/00007890-199707150-00008","article-title":"SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and invivo.","volume":"64","author":"Schuler","year":"1997","journal-title":"Transplantation"},{"key":"R84-12-20210129","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1097\/TP.0b013e3181874a36","article-title":"Effects of immunosuppressive drugs on purified human B cells: evidence supporting the use of MMF and rapamycin.","volume":"86","author":"Heidt","year":"2008","journal-title":"Transplantation"},{"key":"R85-12-20210129","first-page":"544","article-title":"Inhibition of T and B lymphocyte proliferation by rapamycin.","volume":"72","author":"Kay","year":"1991","journal-title":"Immunology"},{"key":"R86-12-20210129","first-page":"405","article-title":"Comparative analysis of drug action on B-cell proliferation and differentiation for mycophenolic acid, everolimus, and prednisolone.","volume":"97","author":"Haneda","year":"2014","journal-title":"Transplantation"},{"key":"R87-12-20210129","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1006\/cimm.1994.1193","article-title":"Inhibition of human B lymphocyte cell cycle progression and differentiation by rapamycin.","volume":"156","author":"Aagaard-Tillery","year":"1994","journal-title":"Cell Immunol"},{"key":"R88-12-20210129","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1111\/j.1432-2277.2012.01537.x","article-title":"Effects of sotrastaurin, mycophenolic acid and everolimus on human B-lymphocyte function and activation.","volume":"25","author":"Matz","year":"2012","journal-title":"Transpl Int"},{"key":"R89-12-20210129","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.trim.2010.06.012","article-title":"In vitro effects of everolimus and intravenous immunoglobulin on cell proliferation and apoptosis induction in the mixed lymphocyte reaction.","volume":"23","author":"Amet","year":"2010","journal-title":"Transpl Immunol"},{"key":"R90-12-20210129","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.healun.2008.01.006","article-title":"Effects of cyclosporine, tacrolimus and sirolimus on vascular changes related to immune response.","volume":"27","author":"Rigol","year":"2008","journal-title":"J Heart Lung Transplant"},{"key":"R91-12-20210129","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.1016\/j.transproceed.2010.07.045","article-title":"Number of peripheral blood regulatory T cells and lymphocyte activation at 3 months after conversion to mTOR inhibitor therapy.","volume":"42","author":"San Segundo","year":"2010","journal-title":"Transplant Proc"},{"key":"R92-12-20210129","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.1016\/j.transproceed.2007.09.015","article-title":"The influence of immunosuppressive therapy on the development of CD4CD25 T cells after renal transplantation.","volume":"39","author":"Korczak-Kowalska","year":"2007","journal-title":"Transplant Proc"},{"key":"R93-12-20210129","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.trim.2010.04.004","article-title":"Preferential increase in memory and regulatory subsets during T-lymphocyte immune reconstitution after thymoglobulin induction therapy with maintenance sirolimus vs cyclosporine.","volume":"23","author":"Morelon","year":"2010","journal-title":"Transpl Immunol"},{"key":"R94-12-20210129","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1097\/01.tp.0000284808.28353.2c","article-title":"Sirolimus versus cyclospoirne therapy increases circulating regulatory T cells, but does not protect renal transplant patients given alemtuzumab induction from chronic allograft injury.","volume":"84","author":"Ruggenenti","year":"2007","journal-title":"Transplantation"},{"key":"R95-12-20210129","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1681\/ASN.2006101143","article-title":"Regulatory T cells and T cell depletion: role of immunosuppressive drugs.","volume":"18","author":"Noris","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"R96-12-20210129","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.4049\/jimmunol.180.4.2357","article-title":"HLA class I antibody-mediated endothelial cell proliferation via the mTOR pathway.","volume":"180","author":"Jindra","year":"2008","journal-title":"J Immunol"},{"key":"R97-12-20210129","doi-asserted-by":"crossref","first-page":"170","DOI":"10.4049\/jimmunol.132.1.170","article-title":"Multiple mechanisms of B cell immunoregulation in man after administration of in vivo corticosteroids.","volume":"132","author":"Cupps","year":"1984","journal-title":"J Immunol"},{"key":"R98-12-20210129","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa1009546","article-title":"INTAC Study Group. Alemtuzumab induction in renal transplantation.","volume":"364","author":"Hanaway","year":"2011","journal-title":"N Engl J Med"},{"key":"R99-12-20210129","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1681\/ASN.2008101037","article-title":"Daclizimab versus antithymocyte globulin in high-immunological-risk renal transplant recipients.","volume":"20","author":"Noel","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"R100-12-20210129","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1056\/NEJMoa060068","article-title":"Thymoglobulin Induction Study Group. Rabbit antithymocyte globulin versus basiliximab in renal transplantation.","volume":"355","author":"Brennan","year":"2006","journal-title":"N Engl J Med"},{"key":"R101-12-20210129","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1097\/TP.0000000000000031","article-title":"Antithymocyte globulin is associated with a lower incidence of de novo donor-specific antibodies in moderately sensitized renal transplant recipients.","volume":"97","author":"Brokhof","year":"2014","journal-title":"Transplantation"},{"key":"R102-12-20210129","doi-asserted-by":"crossref","first-page":"2818","DOI":"10.4049\/jimmunol.1203261","article-title":"In kidney transplant patients, alemtuzumab but not basiliximablow-dose rabbit anti-thymocyte globulin induces B cell depletion and regeneration, which associates with a high incidence of de novo donor-specific anti-HLA antibody development.","volume":"191","author":"Todeschini","year":"2013","journal-title":"J Immunol"},{"key":"R103-12-20210129","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1097\/01.tp.0000418580.88642.e1","article-title":"A randomized, double-blind, placebo-controlled study of singe dose rituximab as induction in renal transplantation: a 3-year follow-up.","volume":"94","author":"Tyden","year":"2012","journal-title":"Transplantation"},{"key":"R104-12-20210129","doi-asserted-by":"crossref","first-page":"3142","DOI":"10.1111\/ajt.12493","article-title":"Randomized controlled pilot study of B cell-targeted induction therapy in HLA sensitized kidney transplant recipients.","volume":"13","author":"Ejaz","year":"2013","journal-title":"Am J Transplant"},{"key":"R105-12-20210129","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1016\/S0140-6736(14)61095-3","article-title":"3C Study Collaborative Group, Haynes R, Harden P, Judge P, et al. Alemtuzumab-based induction treatment versus basiliximab-based induction treatment in kidney transplantation (the 3C Study): a randomised trial.","volume":"384","year":"2014","journal-title":"Lancet"},{"key":"R106-12-20210129","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/TP.0b013e31818c6db0","article-title":"Alemtuzumab induction and antibody-mediated kidney rejection after simultaneous pancreas-kidney transplantation.","volume":"87","author":"Pascual","year":"2009","journal-title":"Transplantation"},{"key":"R107-12-20210129","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1097\/01.TP.0000134398.86243.81","article-title":"Correlation between human leukocyte antigen antibody production and serum creatinine in patients receiving sirolimus monotherapy after Campath-1H induction.","volume":"78","author":"Cai","year":"2004","journal-title":"Transplantation"},{"key":"R108-12-20210129","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/ki.2013.291","article-title":"Neither pre-transplant rituximab nor splenectomy affects de novo HLA antibody production after renal transplantation.","volume":"85","author":"Ashimine","year":"2014","journal-title":"Kidney Int"},{"key":"R109-12-20210129","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/j.1600-6143.2011.03830.x","article-title":"Chronic antibody-mediated rejection is reduced by targeting B-cell immunity during an introductory period.","volume":"12","author":"Kohei","year":"2012","journal-title":"Am J Transplant"},{"key":"R110-12-20210129","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1097\/TP.0b013e3182a688c0","article-title":"Crossmatch-positive liver transplantation in patients receiving thymoglobulin-rituximab induction.","volume":"97","author":"Kubal","year":"2014","journal-title":"Transplantation"},{"key":"R111-12-20210129","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1002\/lt.23381","article-title":"Immunosuppression induction with rabbit anti-thymocyte globulin with or without rituximab in 1000 liver transplant patients with long-term follow-up.","volume":"18","author":"Mangus","year":"2012","journal-title":"Liver Transpl"},{"key":"R112-12-20210129","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1097\/TP.0b013e31816dd450","article-title":"Induction immunosuppression with thymoglobulin and rituximab in intestinal and multivisceral transplantation.","volume":"85","author":"Vianna","year":"2008","journal-title":"Transplantation"},{"key":"R113-12-20210129","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.1056\/NEJMc0808481","article-title":"B-cell-depleting induction therapy and acute cellular rejection.","volume":"360","author":"Clatworthy","year":"2009","journal-title":"N Engl J Med"},{"key":"R114-12-20210129","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/tri.12267","article-title":"Influence of preoperative anti-HLA antibodies on short- and long-term graft survival in recipients with or without rituximab treatment.","volume":"27","author":"Ishida","year":"2014","journal-title":"Transpl Int"},{"key":"R115-12-20210129","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.healun.2014.09.019","article-title":"Preemptive treatment with therapeutic plasma exchange and rituximab for early donor-specific antibodies after lung transplantation.","volume":"34","author":"Ius","year":"2015","journal-title":"J Heart Lung Transplant"},{"key":"R116-12-20210129","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1016\/j.healun.2011.08.009","article-title":"Reduction of alloantibodies via proteasome inhibition in cardiac transplantation.","volume":"30","author":"Patel","year":"2011","journal-title":"J Heart Lung Transplant"},{"key":"R117-12-20210129","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/TP.0b013e3181c6ff8d","article-title":"Proteasome inhibitor-based primary therapy for antibody-mediated renal allograft rejection.","volume":"89","author":"Walsh","year":"2010","journal-title":"Transplantation"},{"key":"R118-12-20210129","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1097\/TP.0b013e318190af83","article-title":"Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection.","volume":"86","author":"Everly","year":"2008","journal-title":"Transplantation"},{"key":"R119-12-20210129","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1097\/TP.0b013e3182911739","article-title":"Proteasome inhibition profoundly affects activated human B cells.","volume":"95","author":"Mulder","year":"2013","journal-title":"Transplantation"},{"key":"R120-12-20210129","doi-asserted-by":"crossref","first-page":"609","DOI":"10.6002\/ect.2012.0131","article-title":"Treatment of antibody-mediated rejection in kidney transplant recipients: a single-center experience with a bortezomib-based regimen.","volume":"10","author":"Nigos","year":"2012","journal-title":"Exp Clin Transplant"},{"key":"R121-12-20210129","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1089\/ars.2014.5892","article-title":"Review of bortezomib treatment of antibody-mediated rejection in renal transplantation.","volume":"21","author":"Ejaz","year":"2014","journal-title":"Antioxid Redox Signal"},{"key":"R122-12-20210129","first-page":"387","article-title":"High immunologic risk living donor kidney transplant using bortezomib in a novel induction regimen without acute antibody mediated rejection.","volume":"381-","author":"Dunn","year":"2011","journal-title":"Clin Transpl"},{"key":"R123-12-20210129","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/TP.0b013e3181dde912","article-title":"Clonal deletion with bortezomib followed by low or no maintenance immunosuppression in renal allograft recipients.","volume":"90","author":"Trivedi","year":"2010","journal-title":"Transplantation"},{"key":"R124-12-20210129","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/TP.0b013e31823f7eea","article-title":"Rapid reduction in donor-specific anti-human leukocyte antigen antibodies and reversal of antibody-mediated rejection with bortezomib in pediatric heart transplant patients.","volume":"93","author":"Morrow","year":"2012","journal-title":"Transplantation"},{"key":"R125-12-20210129","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/j.1600-6143.2005.00749.x","article-title":"Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties.","volume":"5","author":"Larsen","year":"2005","journal-title":"Am J Transplant"},{"key":"R126-12-20210129","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/j.1600-6143.2009.03005.x","article-title":"A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study).","volume":"10","author":"Vincenti","year":"2010","journal-title":"Am J Transplant"},{"key":"R127-12-20210129","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/j.1600-6143.2010.03016.x","article-title":"A Phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study).","volume":"10","author":"Durrbach","year":"2010","journal-title":"Am J Transplant"},{"key":"R128-12-20210129","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1097\/TP.0b013e3181ff87cd","article-title":"Belatacept-based regimens versus a cyclosporine A-based regimen in kidney transplant recipients: 2-year results from the BENEFIT and BENEFIT-EXT studies.","volume":"90","author":"Larsen","year":"2010","journal-title":"Transplantation"},{"key":"R129-12-20210129","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1600-6143.2011.03785.x","article-title":"Three-year outcomes from BENEFIT, a randomized, active-controlled, parallel-group study in adult kidney transplant recipients.","volume":"12","author":"Vincenti","year":"2012","journal-title":"Am J Transplant"},{"key":"R130-12-20210129","first-page":"199","article-title":"Donor-specific HLA antibodies in chronic renal allograft rejection: a prospective trial with a four-year follow-up.","volume":"171-","author":"Lachmann","year":"2006","journal-title":"Clin Transpl"},{"key":"R131-12-20210129","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1097\/TP.0b013e31827d62e3","article-title":"Incidence and impact of de novo donor-specific alloantibody in primary renal allografts.","volume":"95","author":"Everly","year":"2013","journal-title":"Transplantation"},{"key":"R132-12-20210129","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1111\/j.1432-2277.2012.01465.x","article-title":"Everolimus plus early tacrolimus minimization: a phase III, randomized, open-label, multicentre trial in renal transplantation.","volume":"25","author":"Langer","year":"2012","journal-title":"Transpl Int"},{"key":"R133-12-20210129","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1097\/TP.0b013e3181bb43ec","article-title":"Everolimus with very low-exposure cyclosporine a in de novo kidney transplantation: a multicenter, randomized, controlled trial.","volume":"88","author":"Salvadori","year":"2009","journal-title":"Transplantation"},{"key":"R134-12-20210129","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1038\/ki.2010.269","article-title":"Maintenance immunosuppressive therapy with everolimus preserves humoral immune responses.","volume":"78","author":"Struijk","year":"2010","journal-title":"Kidney Int"},{"key":"R135-12-20210129","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1046\/j.1523-1755.2002.00425.x","article-title":"Immune responsiveness in renal transplant recipients: mycophenolic acid severely depresses humoral immunity in vivo.","volume":"62","author":"Rentenaar","year":"2002","journal-title":"Kidney Int"},{"key":"R136-12-20210129","first-page":"336","article-title":"Post-transplant donor-specific antibody production and graft outcome in kidney transplantation: results of sixteen-year monitoring by flow cytometry.","volume":"323-","author":"Piazza","year":"2006","journal-title":"Clin Transpl"},{"key":"R137-12-20210129","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1111\/tri.12334","article-title":"Predictive factors of allosensitization in renal transplant patients switched from calcineurin to mTOR inhibitors.","volume":"27","author":"Ruiz San Millan","year":"2014","journal-title":"Transpl Int"},{"key":"R138-12-20210129","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1111\/ctr.12418","article-title":"Evolution of donor-specific antibodies (DSA) and incidence of de novo DSA in solid organ transplant recipients after switch to everolimus alone or associated with low dose of calcineurin inhibitors.","volume":"28","author":"Perbos","year":"2014","journal-title":"Clin Transplant"},{"key":"R141-12-20210129","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1097\/TP.0b013e31824f3d7c","article-title":"Using donor-specific antibodies to monitor the need for immunosuppression.","volume":"93","author":"Hoshino","year":"2012","journal-title":"Transplantation"},{"key":"R142-12-20210129","doi-asserted-by":"crossref","first-page":"280rv2","DOI":"10.1126\/scitranslmed.aaa6853","article-title":"Advances and challenges in immunotherapy for solid organ and hematopoietic stem cell transplantation.","volume":"7","author":"McDonald-Hyman","year":"2015","journal-title":"Sci Transl Med"},{"key":"R143-12-20210129","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1097\/BOR.0000000000000000","article-title":"B cells: depletion or functional modulation in rheumatic diseases.","volume":"26","author":"Dorner","year":"2014","journal-title":"Curr Opin Rheumatol"},{"key":"R144-12-20210129","doi-asserted-by":"crossref","first-page":"456037","DOI":"10.1155\/2014\/456037","article-title":"Salvage therapy of multiple myeloma: the new generation drugs.","volume":"2014","author":"Romano","year":"2014","journal-title":"Biomed Res Int"},{"key":"R145-12-20210129","doi-asserted-by":"crossref","first-page":"705","DOI":"10.4049\/jimmunol.176.2.705","article-title":"A case for regulatory B cells.","volume":"176","author":"Mizoguchi","year":"2006","journal-title":"J Immunol"},{"issue":"Suppl 1","key":"R146-12-20210129","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1186\/ar3910","article-title":"B-cell depletion in SLE: clinical and trial experience with rituximab and ocrelizumab and implications for study design.","volume":"15","author":"Reddy","year":"2013","journal-title":"Arthritis Res Ther"},{"issue":"Suppl 5","key":"R147-12-20210129","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1186\/ar3909","article-title":"Rationale of anti-CD19 immunotherapy: an option to target aut12oreactive plasma cells in autoimmunity.","volume":"14","author":"Mei","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"R148-12-20210129","doi-asserted-by":"crossref","first-page":"R204","DOI":"10.1186\/ar3179","article-title":"Epratuzumab targeting of CD22 affects adhesion molecule expression and migration of B-cells in systemic lupus erythematosus.","volume":"12","author":"Daridon","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"R149-12-20210129","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1002\/art.37818","article-title":"CD22 ligation inhibits downstream B cell receptor signaling and Ca(2) flux upon activation.","volume":"65","author":"Sieger","year":"2013","journal-title":"Arthritis Rheum"},{"key":"R150-12-20210129","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/nrrheum.2014.33","article-title":"The BAFFAPRIL system in SLE pathogenesis.","volume":"10","author":"Vincent","year":"2014","journal-title":"Nat Rev Rheumatol"},{"key":"R151-12-20210129","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1111\/ajt.13045","article-title":"Neutralizing BAFFAPRIL with atacicept prevents early DSA formation and AMR development in T cell depletion induced nonhuman primate AMR model.","volume":"15","author":"Kwun","year":"2015","journal-title":"Am J Transplant"},{"key":"R152-12-20210129","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.cytogfr.2013.04.003","article-title":"The BAFFAPRIL system: emerging functions beyond B cell biology and autoimmunity.","volume":"24","author":"Vincent","year":"2013","journal-title":"Cytokine Growth Factor Rev"},{"key":"R153-12-20210129","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1172\/JCI71602","article-title":"Emerging therapies targeting the ubiquitin proteasome system in cancer.","volume":"124","author":"Weathington","year":"2014","journal-title":"J Clin Invest"},{"key":"R154-12-20210129","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1111\/j.1365-2141.2012.09232.x","article-title":"An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed andor refractory multiple myeloma who have been previously treated with bortezomib.","volume":"158","author":"Vij","year":"2012","journal-title":"Br J Haematol"},{"key":"R155-12-20210129","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.leukres.2013.10.018","article-title":"New orally active proteasome inhibitors in multiple myeloma.","volume":"38","author":"Allegra","year":"2014","journal-title":"Leuk Res"},{"key":"R156-12-20210129","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1111\/j.1600-6143.2011.03929.x","article-title":"Deleterious effect of CTLA4-Ig on a Treg-dependent transplant model.","volume":"12","author":"Riella","year":"2012","journal-title":"Am J Transplant"},{"key":"R157-12-20210129","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1111\/ajt.12810","article-title":"Belatacept-based immunosuppression in de novo liver transplant recipients: 1-year experience from a phase II randomized study.","volume":"14","author":"Klintmalm","year":"2014","journal-title":"Am J Transplant"},{"key":"R158-12-20210129","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1111\/j.1600-6143.2011.03509.x","article-title":"CD40-specific costimulation blockade enhances neonatal porcine islet survival in nonhuman primates.","volume":"11","author":"Thompson","year":"2011","journal-title":"Am J Transplant"},{"key":"R159-12-20210129","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1111\/j.1600-6143.2010.03212.x","article-title":"Experience with a novel efalizumab-based immunosuppressive regimen to facilitate single donor islet cell transplantation.","volume":"10","author":"Turgeon","year":"2010","journal-title":"Am J Transplant"},{"key":"R160-12-20210129","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.imlet.2013.08.009","article-title":"The effect of MICA antigens on kidney transplantation outcomes.","volume":"156","author":"Luo","year":"2013","journal-title":"Immunol Lett"},{"issue":"Suppl 1","key":"R161-12-20210129","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/nep.12421","article-title":"Angiotensin II type 1 receptor antibody precipitating acute vascular rejection in kidney transplantation.","volume":"20","author":"Jobert","year":"2015","journal-title":"Nephrology (Carlton)"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000000869","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,13]],"date-time":"2023-08-13T12:34:52Z","timestamp":1691930092000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007890-201601000-00012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":159,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/tp.0000000000000869","relation":{},"ISSN":["0041-1337"],"issn-type":[{"value":"0041-1337","type":"print"}],"subject":[],"published":{"date-parts":[[2016,1]]}}}